Given the apparent discordance between the early tumor initiation phenotypes and subsequent tumor growth, we next sought to better understand the molecular impact that loss of WT Kras has in the context of an oncogenic KrasG12D mutant in pancreatic tumors in vivo. This evidence concerns the gene KRAS and neoplasm.